WQ92928 (e) Tabled on 17/05/2024

What assessment has the Cabinet Secretary made of the impact of long-term disruptions to the supply of the pancreatic enzyme replacement therapy, creon, on the health of people with cystic fibrosis?

Answered by Cabinet Secretary for Health and Social Care | Answered on 21/05/2024

The disruption to the supply of these medicines is unsettling for those who have been prescribed them.

Maintaining the continuity of supply of medicines to the UK is a reserved matter and is the responsibility of the UK Government.

Currently there are supply disruptions affecting a number of Pancreatic enzyme replacement therapies (PERT):

  • Creon 10,000 and 25,000 gastro-resistant capsules are expected to be out of stock until 2026.
  • Nutrizym® 22 capsules are out of stock until mid-August 2024.

Managing the implications of supply disruptions for patients and the NHS requires co-ordinated action between the UK and devolved governments, and the NHS. The Welsh Government’s Medicines Shortages web page offers general advice on why shortages occur and how they are managed.



A medicines shortage letter was issued to all GPs, pharmacies and hospitals in Wales on 13 May, providing advice on the mitigating actions that need to be taken during the supply disruption.

Pancrex V® capsules and powder remain available, unfortunately the manufacturer is unable to fully meet the increase in demand. Pharmacies and hospitals can source unlicensed supplies of Creon® 10,000 and 25,000 gastro-resistant capsules and alternative brands of PERT however lead times may vary.

Anyone who is having difficulty obtaining treatment should contact their doctor or pharmacist to discuss what alternatives might be available.